Verastem, Inc.
VSTMVerastem, Inc. (VSTM) is a biotechnology company focused on developing and commercializing medicines for cancer treatment. The company emphasizes targeting cancer stem cells to improve therapy outcomes, with a portfolio that includes drugs aimed at Kuren and other oncology indications. Founded in 2010, Verastem aims to advance innovative approaches to solid tumor and hematologic cancers.
Company News
The KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk. Find out why VSTM stock is a Buy.
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Avoid these mistakes when you're trading penny stocks The post Trading Penny Stocks This Week? 3 Mistakes to Avoid appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
